Covered recipient · General Payments record
MARTHA HERNANDEZ ILLAS
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$163.00
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $163.00 | 4 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $125.00 | 1 |
| PFIZER INC. | $38.00 | 3 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARTHA HERNANDEZ ILLAS
NPI 1972517464 · CMS profile ID 733063
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
FORT LAUDERDALE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $163.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $15.46 | 09/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672777395 | CMS |
| Amgen Inc. | $125.00 | 08/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662726285 | CMS |
| PFIZER INC. | $6.75 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672054747 | CMS |
| PFIZER INC. | $15.79 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672016437 | CMS |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2019 | $163.00 | 4 |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019
- Generated from
- OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,780,360.32 | 3 |
| PY2024 | Principal investigator | $1,857,594.44 | 9 |
| PY2023 | Principal investigator | $2,411,538.38 | 25 |
| PY2022 | Recipient | $8,492.00 | 4 |
| PY2022 | Principal investigator | $6,968,480.90 | 32 |
| PY2021 | Principal investigator | $4,588,067.03 | 55 |
| PY2020 | Recipient | $1,800.00 | 2 |
| PY2020 | Principal investigator | $1,389,670.25 | 53 |
| PY2019 | Principal investigator | $5,017,814.30 | 57 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $251,187.90 | 12/31/2021 | Non-covered Recipient Entity QPS MIAMI RESEARCH ASSOCIATES | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults | No dispute reported | 06/30/2026 | 848738949 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $42.00 | 12/31/2021 | Non-covered Recipient Entity QPS MRA, LLC EARLY PHASE | An Open-Label, Single-Dose, 3-Period, Fixed Sequence Study to Determine the Effect of Food and a Proton Pump Inhibitor on Gefapixant MK-7264 F04B Pharmacokinetics in Healthy Participants. | No dispute reported | 06/30/2026 | 848754213 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $729.60 | 12/31/2021 | Non-covered Recipient Entity QPS MRA, LLC EARLY PHASE | A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Participants | No dispute reported | 06/30/2026 | 848756915 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $72.46 | 12/31/2021 | Non-covered Recipient Entity QPS MRA, LLC EARLY PHASE | A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Participants | No dispute reported | 06/30/2026 | 848756917 |
| Principal investigator 1 | PFIZER INC. | $242,814.50 | 12/23/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 OPEN LABEL FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 832551817 |
| Principal investigator 1 | PFIZER INC. | $20,460.72 | 12/16/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832586513 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $83,756.81 | 12/09/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831015013 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 12/08/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551827 |
| Principal investigator 1 | Amgen Inc. | $220,720.00 | 11/27/2021 | Non-covered Recipient Entity QPS MIAMI RESEARCH ASSOCIATES | AMG 598 - Ph 1 Safety; Tolerability; PK and PD of MAD | No dispute reported | 06/30/2026 | 830980001 |
| Principal investigator 1 | PFIZER INC. | $58,980.50 | 11/23/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 OPEN LABEL FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 832551715 |
| Principal investigator 1 | PFIZER INC. | $4,510.00 | 11/16/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832766655 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $2,520.00 | 11/04/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831014972 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $92,344.21 | 11/04/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831014977 |
| Principal investigator 1 | H. Lundbeck A S | $26,161.42 | 11/03/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179406072 |
| Principal investigator 1 | PFIZER INC. | $17,607.33 | 10/29/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832843299 |
| Principal investigator 1 | PFIZER INC. | $85,934.00 | 10/08/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551537 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $93,036.67 | 10/01/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831014951 |
| Principal investigator 1 | PFIZER INC. | $20,460.72 | 09/29/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832809559 |
| Principal investigator 1 | H. Lundbeck A S | $1,325.00 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405908 |
| Principal investigator 1 | H. Lundbeck A S | $16,097.88 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405910 |
| Principal investigator 1 | H. Lundbeck A S | $17,670.77 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405912 |
| Principal investigator 1 | H. Lundbeck A S | $20,846.21 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405914 |
| Principal investigator 1 | H. Lundbeck A S | $3,213.61 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405916 |
| Principal investigator 1 | H. Lundbeck A S | $325.00 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405918 |
| Principal investigator 1 | H. Lundbeck A S | $8,890.83 | 09/09/2021 | Non-covered Recipient Entity QPS MRA LLC | Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects | No dispute reported | 06/30/2026 | 1179405920 |
| Principal investigator 1 | PFIZER INC. | $540,450.00 | 09/04/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832814567 |
| Principal investigator 1 | PFIZER INC. | $688,805.00 | 09/03/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832708089 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $69,629.60 | 09/02/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831014499 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $602.10 | 08/24/2021 | Non-covered Recipient Entity MIAMI RESEARCH ASSOCIATES LLC | A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE | No dispute reported | 06/30/2026 | 816755109 |
| Principal investigator 1 | PFIZER INC. | $160,834.00 | 08/06/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551705 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $45,208.75 | 07/29/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831014045 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $602.10 | 07/16/2021 | Non-covered Recipient Entity MIAMI RESEARCH ASSOCIATES LLC | A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE | No dispute reported | 06/30/2026 | 816741971 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,709.00 | 07/13/2021 | Non-covered Recipient Entity MIAMI RESEARCH ASSOCIATES | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 816740137 |
| Principal investigator 1 | PFIZER INC. | $291,094.05 | 07/09/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551611 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $3,851.24 | 07/01/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831011867 |
| Principal investigator 1 | PFIZER INC. | $45,500.00 | 06/16/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832733967 |
| Principal investigator 1 | PFIZER INC. | $315,567.14 | 06/05/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551547 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $21,116.23 | 06/03/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831011691 |
| Principal investigator 1 | PFIZER INC. | $229,827.32 | 05/21/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551619 |
| Principal investigator 1 | PFIZER INC. | $25,000.00 | 05/21/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832856359 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.00 | 05/04/2021 | Non-covered Recipient Entity MIAMI RESEARCH ASSOCIATES | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 816719463 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $74,372.09 | 05/03/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831011441 |
| Principal investigator 1 | PFIZER INC. | $28,768.55 | 04/06/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 832551527 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $183,052.00 | 04/01/2021 | Non-covered Recipient Entity BIO KINETIC CLINICAL | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831011201 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $104,077.30 | 03/25/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831011141 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $44,057.78 | 02/25/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831010963 |
| Principal investigator 1 | Amgen Inc. | $4,275.00 | 02/23/2021 | Non-covered Recipient Entity QPS MIAMI RESEARCH ASSOCIATES | AMG 890_FIH/ SAD | No dispute reported | 06/30/2026 | 830980263 |
| Principal investigator 1 | PFIZER INC. | $157,024.00 | 02/23/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832719433 |
| Principal investigator 1 | PFIZER INC. | $14,425.00 | 02/05/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832758597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1.94 | 02/04/2021 | Non-covered Recipient Entity QPS MRA LLC | A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE | No dispute reported | 06/30/2026 | 793093919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,345.90 | 02/04/2021 | Non-covered Recipient Entity QPS MRA LLC | A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE | No dispute reported | 06/30/2026 | 793093921 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $766.80 | 01/26/2021 | Non-covered Recipient Entity MIAMI RESEARCH ASSOCIATES | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 816685513 |
| Principal investigator 1 | PFIZER INC. | $1,898.00 | 01/16/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832755839 |
| Principal investigator 1 | Noven Pharmaceuticals, Inc. | $37,500.00 | 01/14/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES | No dispute reported | 06/30/2026 | 831010796 |
| Principal investigator 1 | PFIZER INC. | $189,319.00 | 01/12/2021 | Non-covered Recipient Entity QPS MRA LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 832727003 |